Articles by Mathini Ilancheran

  1. Accelerating Clinical Trial Patient Engagement & Retention Through Mobile Technology 3/23/2017

    This article assesses the mobile health apps market, key features of successful apps, and associated timelines and costs for developing apps that engage patients across categories and conditions.

  2. Improving Patient Retention & Engagement Through Health Programs 12/21/2016

    Patient recruitment is often highlighted as the key factor in ensuring clinical study success. Ensuring on-time enrolments of patients, investigators, etc. is a constant concern throughout the clinical trial phases. However, patient retention through engagement is also a key factor — and one that is often overlooked. Patient dropout rates for pharmaceutical clinical trials are estimated to range between 15 to 40 percent of enrolled participants, depending on the trial phase.

  3. Phase I Clinical Supply Landscape: Trends, Demarcation And Security 8/30/2016

    The core addressable early phase market is USD 11.9 billion growing with a CAGR of 2 – 3 percent. Early-phase trials are outsourced at greater than 60 percent by pharma, as the trials are costly and small in number. The supply market for early phase is comprised by CROs, research centers, and academic institutes. The market size that is comprised by the CROs is estimated to be around USD 8 billion, which is about 67 percent of the early phase market.

  4. Understanding Key Early Phase Clinical Trial Cost Drivers 5/19/2015

    Pharmaceutical companies have been implementing intensive cost–saving efforts in the recent years through mergers, reducing overheads, and trimming down of entire business units for efficiency. These efforts have increased the need to outsource services to external vendors throughout the R&D value chain. The early phase clinical trial market in 2014 saw an approximate outsourcing rate of 56 percent with most of the patient studies being externalized to both global and specialist CROs. As cost efficiency is the main focus for pharma, it is important to understand the cost behavior of outsourcing services.

  5. Investigator Payments – Channels, Cycle Time and Benchmarks 2/26/2015

    Considering the fair market value for investigator payments per trial costs is crucial in order to avoid higher payment which may result in financial strain on the sponsor. 

  6. Clinical Resource Profiles – Standardization & Benchmarking As An Outcome Of Strategic Insourcing 10/30/2014

    Non-standardization of resource profiles across clinical departments, before running any Rfx process to obtain contract rates from suppliers creates data discrepancy with multiple contract rates from numerous suppliers. On negotiation, supplier’s claim their resource has additional skills and possesses more experience than others. Lack of standardized and benchmarked resource profile internally does not allow comparison of quotes received, hence weakening the negotiation process. This is an ongoing problem that pharmaceutical companies are facing and there is need to create standards for each clinical department. Additionally, benchmarking market rates for each of the standardized resource profile and understanding utilisation rate for the resources is important as it acts as the main lever during the entire process. 

    This whitepaper will explore the Outsourced CRO market, Need for standardization & benchmarking market rates and case study of Clinical resource contract rates.